In the current trading session, at last check, Advaxis Inc., ADXS stock had surged by 54.09% to trade at the price of $0.74. ADXS stock previously closed the session at $0.49. The ADXS stock volume traded at 33.69 million shares, which was higher than the average three-month volume of 6.50 million shares within the past 3 months. In the past year up to date, ADXS stock had shed -32.73% however in the past week the shares have moved up by 18.98%. In the past three and six months, the stock has lost -65.58% and added 21.33%. Furthermore, Advaxis Inc. is currently valued in the market at $62.08 million and has 137.96 million outstanding shares.
What you need to know about Advaxis Inc.
Advaxis, Inc.is a clinical-stage biotechnology company that centers on the innovation, development, and commercialization of Listeria monocytogenes (Lm) technology antigen delivery products. The company has its base of operations in the United States. ADXS stock’s product offerings include the development of ADXS-PSA, which is aimed to be used for the therapy of metastatic prostate malignant cancer and which is in the Phase 2 clinical stage.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ADXS-503 is used for the therapy of non-small cell lung cancer and is in Phase 1/2 clinical trial; and ADXS-504 for the therapy of prostate disease.
It is likewise leading clinical investigations of Lm Technology immunotherapies in the specific areas of illnesses and diseases focused hotspot/off-the-rack neoantigen-coordinated treatments; human papilloma infection-related tumors; and prostate malignancy.
Advaxis is taking part in a presentation at ASCO Annual Meeting
ADXS stock announced that it will present information from Part B of the Phase 1 investigation of ADXS-503 in the mix with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting being held basically, on June 4-8, 2021. The subtleties of the presentation incorporate; the title of the show; “A stage 1 investigation of an off-the-rack, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-little cell cellular breakdown in the lungs (NSCLC) advancing on pembrolizumab as last treatment”. The meeting will be a Poster Session type.
Achieving milestone in the trial of ADXS321-164
The Company has accomplished the second achievement under its authorizing arrangement for ADXS31-164, otherwise called ADXS-HER2, to OS Therapies for assessment in the treatment of osteosarcoma in people.
This financing achievement for OS Therapies brings OST-HER2, originally ADXS-HER2, one step closer to the clinic. The OST-HER2 has a potential that ADXS stock is in to invest in and has been approved in the U.S. for the adjuvant treatment of osteosarcoma in canines, and has assumed a part in the improvement of this significant new contender for osteosarcoma patients. The group at OST will be propelling the program, expanding upon its beginning stage 1 information assessing ADXS-HER2.
This achievement phase will give Advaxisboost in the capital as ADXS accelerates across its developing ADXS-HOT neoantigen-coordinated off-the-rack clinical projects. If the company can leverage these resources while advancing in ADXS-503and ADXS-504 which is on track to enter the clinic in Q2 2021 then it will progress immensely in its pipeline achievements and progress which can translate to a positive response from investors.
